Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | Phase 1 | withdrawn | Mar 22, 2021 | Duke University | Study halted prematurely, prior to enrollment of first participant. | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute… | Phase 1 | terminated | Sep 2, 2021 | Beijing Boren Hospital | ethic commitee decision | Other (stated, no rule matched) |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory… | Phase 1 | withdrawn | Mar 4, 2022 | Beijing Boren Hospital | Difficulty in joining the group | Other (stated, no rule matched) |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in… | Phase 2 | terminated | Feb 21, 2021 | Ensoma | This study was voluntarily terminated due to a business decision not to proceed and not due to any… | Safety / toxicity |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | Phase 1 | terminated | Nov 1, 2022 | Institute of Hematology & Blood Diseases Hospital, China | It did not reach the expected results of clinical trial | Other (stated, no rule matched) |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of… | Phase 1 | terminated | Nov 20, 2015 | Astellas Pharma Global Development, Inc. | Business decision by sponsor | Sponsor / business decision |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT04523623 | Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated… | N/A | withdrawn | Aug 21, 2020 | Washington University School of Medicine | Project canceled for other reason , describe: - Lack of enrollment Project canceled - lack of… | Enrollment / accrual |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in… | Phase 1 | terminated | Aug 12, 2016 | Astellas Pharma Global Development, Inc. | Study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in… | Phase 1 / Phase 2 | terminated | Oct 21, 2014 | Stemline Therapeutics, Inc. | not stated | Not stated |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | — | withdrawn | Aug 30, 2022 | Dana-Farber Cancer Institute | Funding for study was withdrawn | Funding |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With…(20170528) | Phase 1 | terminated | May 30, 2018 | Amgen | Premature discontinuation of study, a strategic decision. | Sponsor / business decision |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Jul 29, 2021 | Guenther Koehne | Could not accrue | Enrollment / accrual |
| NCT04322084 | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With… | — | withdrawn | Mar 26, 2020 | St. Jude Children's Research Hospital | The study was activated at the onset of the COVID pandemic. At that time voluntary, non-therapeutic… | COVID-19 / pandemic |
| NCT01174615 | Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal… | — | withdrawn | Aug 3, 2010 | University of Massachusetts, Worcester | Withdrawing as this is not a clinical trial | Other (stated, no rule matched) |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 8, 2018 | M.D. Anderson Cancer Center | This study was terminated early due to other competing trials, therefore did not go on to the Phase… | Other (stated, no rule matched) |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | Phase 1 | terminated | Oct 26, 2021 | Medical College of Wisconsin | Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All… | Other (stated, no rule matched) |
| NCT05682170 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | terminated | Jan 12, 2023 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with… | Phase 1 | withdrawn | Apr 21, 2023 | City of Hope Medical Center | Withdrawn -ctms | Other (stated, no rule matched) |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid… | Phase 2 | withdrawn | May 11, 2023 | Wake Forest University Health Sciences | PI decided not to move forward with the study | Other (stated, no rule matched) |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Institute of Hematology & Blood Diseases Hospital, China | withdrawn | Other (stated, no rule matched) |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance… | Phase 1 / Phase 2 | terminated | May 16, 2017 | BioLineRx, Ltd. | Due to lack of enrollment | Enrollment / accrual |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT05375253 | Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for… | Phase 1 | withdrawn | May 16, 2022 | University of Nebraska | PI has left institution and is taking the study with him. | Other (stated, no rule matched) |
| NCT03603964 | Guadecitabine Extension Study | Phase 2 | terminated | Jul 27, 2018 | Astex Pharmaceuticals, Inc. | Early termination not due to patient safety | Safety / toxicity |
| NCT04996745 | Taking POSNA's OrthoKids to the People | N/A | withdrawn | Aug 9, 2021 | Louisiana State University Health Sciences Center in New Orleans | Submitted in error | Other (stated, no rule matched) |
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation… | Phase 1 | terminated | Oct 6, 2022 | Malika Kapadia | On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for… | Investigator |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With… | Phase 1 / Phase 2 | terminated | Nov 16, 2018 | Celgene | Absence of significant therapeutic benefit over existing therapies | Other (stated, no rule matched) |
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult…(Pona-CELL) | Phase 2 | terminated | Sep 18, 2020 | Institute of Hematology and Blood Transfusion, Czech Republic | slower recruitment rate; | Enrollment / accrual |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With… | Phase 1 | withdrawn | Aug 23, 2023 | Medical College of Wisconsin | Sponsor withdrew support. | Other (stated, no rule matched) |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | Phase 1 | terminated | Feb 2, 2015 | Menarini Group | The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of… | Safety / toxicity |
| NCT05028751 | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants… | Phase 1 / Phase 2 | terminated | Aug 31, 2021 | Kronos Bio | Sponsor decision | Sponsor / business decision |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive…(Pediatric AML) | Phase 1 | withdrawn | Nov 18, 2022 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | Phase 1 | withdrawn | Nov 11, 2010 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe to… | Safety / toxicity |
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With… | Phase 1 | terminated | Nov 7, 2019 | Astex Pharmaceuticals, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)… | Phase 1 | terminated | Nov 19, 2020 | Astex Pharmaceuticals, Inc. | termination due to portfolio prioritization | Sponsor / business decision |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic… | — | terminated | Apr 21, 2021 | University of Washington | The study ended earlier than anticipated due to slow accrual. | Enrollment / accrual |
| NCT03318016 | Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid… | Phase 1 | terminated | Oct 23, 2017 | University of Colorado, Denver | Low enrollment, University Scientific Review Committee required study closure. | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With… | Phase 3 | terminated | Aug 6, 2018 | GlycoMimetics Incorporated | Trial failed to meet primary endpoint. | Other (stated, no rule matched) |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell… | — | terminated | Dec 9, 2022 | Mustang Bio | Business Reasons | Sponsor / business decision |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With… | Phase 1 | terminated | Sep 14, 2018 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 26, 2024source: clinicaltrials